Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04650321 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Home Based Infusions for Ocrelizumab

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated June 10, 2021 (before its estimated August 31, 2021 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary and study completion dates: Dec 31, 2021 to Aug 31, 2021v5
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Feb 1, 2021 to Mar 1, 2021 · Study description expanded, about 3 wordsv4 Show 2 more changesShow less
    • Start date changed from estimate of Feb 1, 2021 to Mar 1, 2021
    • Study description expanded, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  3. Start date: Jan 1, 2021 to Feb 1, 2021v3
  4. Secondary endpoints: 7 to 8v2 See this version in full on ClinicalTrials.gov ↗
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal is to assess the safety and effectiveness of home ocrelizumab infusion.
Trial Details
NCT Number NCT04650321
Lead Sponsor University of Colorado, Denver
Collaborators: Genentech, Inc.
Conditions Multiple Sclerosis
Enrollment 110 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov